First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.56 Million) by net assets ($257.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TRAXV market cap for the company's overall valuation and market capitalisation.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Cash Flow Conversion Efficiency Trend (2023–2024)
This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's cash flow conversion efficiency has evolved over time, based on yearly financial data.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued ranked by their cash flow conversion efficiency. See TRAXV operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Autohellas S.A.
AT:OTOEL
|
0.064x |
|
Donegal Group A Inc
NASDAQ:DGICA
|
0.009x |
|
Cancom SE
F:COK
|
-0.114x |
|
Basellandschaftliche Kantonalbank
SW:BLKB
|
-0.315x |
|
TTY Biopharm Co Ltd
TWO:4105
|
0.088x |
|
Cass Information Systems Inc
NASDAQ:CASS
|
0.060x |
|
Shenzhen Pacific Union Precision Manufacturing Co. Ltd. A
SHG:688210
|
N/A |
|
Farglory FTZ Investment Holding Co Ltd
TW:5607
|
0.041x |
Annual Cash Flow Conversion Efficiency for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the annual cash flow conversion efficiency of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. View First Tracks Biotherapeutics, Inc. Ordin share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $391.60 Million | $-125.81 Million | -0.321x | -41.57% |
| 2023-12-31 | $409.85 Million | $-93.00 Million | -0.227x | -- |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more